{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:53:08Z","timestamp":1761166388030,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011472","name":"American Academy of Clinical Psychology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005349","name":"American Association of Colleges of Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Graphics and Modelling"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jmgm.2017.10.023","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T22:46:11Z","timestamp":1510267571000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors"],"prefix":"10.1016","volume":"79","author":[{"given":"Syeda Maryam","family":"Azeem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alecia N.","family":"Muwonge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehaben","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina W.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Global AIDS Update","key":"10.1016\/j.jmgm.2017.10.023_bib0005"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-med-011514-023043","article-title":"Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure","volume":"67","author":"Martin","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0015","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"Basson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0020","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1016\/j.bmcl.2013.06.091","article-title":"Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility","volume":"23","author":"Bollini","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","article-title":"Antiretroviral therapy: current drugs","volume":"28","author":"Pau","year":"2014","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0030","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1128\/AAC.00591-12","article-title":"Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors","volume":"56","author":"Asahchop","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0035","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1517\/14656566.2012.729040","article-title":"Treatment of HIV infection with once-daily regimens","volume":"13","author":"Permpalung","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jac\/dks404","article-title":"Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor","volume":"68","author":"Sharma","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0045","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/acsmedchemlett.5b00254","article-title":"Potent inhibitors active against HIV reverse transcriptase with K101P, a mutation conferring rilpivirine resistance","volume":"6","author":"Gray","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/cb200394t","article-title":"Winning the arms race by improving drug discovery against mutating targets","volume":"7","author":"Anderson","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coviro.2013.03.012","article-title":"HIV-1 reverse transcriptase and antiviral drug resistance. Part 1","volume":"3","author":"Das","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.coviro.2013.03.014","article-title":"HIV-1 reverse transcriptase and antiviral drug resistance. Part 2","volume":"3","author":"Das","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/QAD.0b013e3283584500","article-title":"Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies","volume":"27","author":"Anta","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0075","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0080","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1016\/j.bmcl.2013.06.093","article-title":"Extension into the entrance channel of HIV-1 reverse transcriptase?crystallography and enhanced solubility","volume":"23","author":"Bollini","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1742-4690-9-99","article-title":"A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants","volume":"9","author":"Johnson","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0090","first-page":"123","article-title":"HIV prevention: opportunities and challenges","volume":"24","author":"Marrazzo","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0095","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/prot.24551","article-title":"Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction","volume":"82","author":"Zhu","year":"2014","journal-title":"Proteins"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0100","doi-asserted-by":"crossref","first-page":"e82849","DOI":"10.1371\/journal.pone.0082849","article-title":"Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein\u2013protein complexes","volume":"8","author":"Beard","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00277-17","article-title":"In vitro cross-resistance profiles of rilpivirine, dapivirine, and MIV-150, nonnucleoside reverse transcriptase inhibitor microbicides in clinical development for the prevention of HIV-1 infection","volume":"61","author":"Giacobbi","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0110","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/AAC.00986-09","article-title":"TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1","volume":"54","author":"Azijn","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0115","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J. Virol."},{"issue":"Suppl 1","key":"10.1016\/j.jmgm.2017.10.023_bib0120","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0125","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/jm1002233","article-title":"Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design","volume":"53","author":"Lansdon","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0130","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"Das","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0135","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring: 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"year":"2017","series-title":"The PyMOL Molecular Graphics System, Version 1.8","author":"Schrodinger","key":"10.1016\/j.jmgm.2017.10.023_bib0140"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/protein\/gzu017","article-title":"Structure-based approach to the prediction of disulfide bonds in proteins","volume":"27","author":"Salam","year":"2014","journal-title":"Protein Eng. Des. Sel."},{"year":"2017","series-title":"Maestro","author":"Schrodinger","key":"10.1016\/j.jmgm.2017.10.023_bib0150"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0155","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0969-2126(00)00513-X","article-title":"Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase","volume":"8","author":"Ren","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0160","doi-asserted-by":"crossref","first-page":"e0145772","DOI":"10.1371\/journal.pone.0145772","article-title":"HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing","volume":"10","author":"Rhee","year":"2015","journal-title":"PLoS One"},{"issue":"2015","key":"10.1016\/j.jmgm.2017.10.023_bib0165","first-page":"132","article-title":"Update of the drug resistance mutations in HIV-1","volume":"23","author":"Wensing","year":"2015","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0170","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1021\/ct900587b","article-title":"Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field","volume":"6","author":"Shivakumar","year":"2010","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0175","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1021\/ja3092642","article-title":"Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design","volume":"134","author":"Frey","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0180","doi-asserted-by":"crossref","first-page":"13707","DOI":"10.1073\/pnas.1002162107","article-title":"Predicting resistance mutations using protein design algorithms","volume":"107","author":"Frey","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0185","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1021\/jm501908a","article-title":"Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants","volume":"58","author":"Frey","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jviromet.2010.12.001","article-title":"Simple and rapid determination of the enzyme kinetics of HIV-1 reverse transcriptase and anti-HIV-1 agents by a fluorescence based method","volume":"171","author":"Silprasit","year":"2011","journal-title":"J. Virol. Methods"},{"year":"2017","series-title":"GraphPad Prism Version 7.00","key":"10.1016\/j.jmgm.2017.10.023_bib0195"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/prot.21431","article-title":"Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease","volume":"68","author":"Chellappan","year":"2007","journal-title":"Proteins"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0205","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/jac\/dkt166","article-title":"Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission","volume":"68","author":"Arien","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0210","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1021\/bi020461s","article-title":"Structural and thermodynamic studies on a salt-bridge triad in the NADP-binding domain of glutamate dehydrogenase from Thermotoga maritima: cooperativity and electrostatic contribution to stability","volume":"41","author":"Lebbink","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmgm.2017.10.023_bib0215","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3851\/IMP2636","article-title":"96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials","volume":"18","author":"Rimsky","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0220","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.01096-08","article-title":"Reverse transcriptase inhibitors as potential colorectal microbicides","volume":"53","author":"Herrera","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmgm.2017.10.023_bib0225","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/AAC.05821-11","article-title":"In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine","volume":"56","author":"Schader","year":"2012","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Molecular Graphics and Modelling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326317306460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1093326317306460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:56:54Z","timestamp":1761080214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1093326317306460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":45,"alternative-id":["S1093326317306460"],"URL":"https:\/\/doi.org\/10.1016\/j.jmgm.2017.10.023","relation":{},"ISSN":["1093-3263"],"issn-type":[{"type":"print","value":"1093-3263"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Graphics and Modelling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmgm.2017.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}